Vinva Investment Management Ltd Acquires 1,502 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Vinva Investment Management Ltd lifted its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 8.2% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 19,824 shares of the medical research company's stock after purchasing an additional 1,502 shares during the period. Vinva Investment Management Ltd's holdings in Thermo Fisher Scientific were worth $10,285,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in TMO. Howard Capital Management Group LLC increased its stake in shares of Thermo Fisher Scientific by 0.5% in the third quarter. Howard Capital Management Group LLC now owns 54,575 shares of the medical research company's stock worth $33,759,000 after buying an additional 286 shares during the last quarter. Principal Financial Group Inc. increased its stake in shares of Thermo Fisher Scientific by 22.1% in the third quarter. Principal Financial Group Inc. now owns 1,247,838 shares of the medical research company's stock worth $771,876,000 after buying an additional 225,568 shares during the last quarter. GLOBALT Investments LLC GA increased its stake in shares of Thermo Fisher Scientific by 5.0% in the third quarter. GLOBALT Investments LLC GA now owns 1,102 shares of the medical research company's stock worth $682,000 after buying an additional 52 shares during the last quarter. Baron Wealth Management LLC increased its stake in Thermo Fisher Scientific by 2.1% during the third quarter. Baron Wealth Management LLC now owns 1,345 shares of the medical research company's stock valued at $832,000 after purchasing an additional 28 shares during the last quarter. Finally, Aviance Capital Partners LLC increased its stake in Thermo Fisher Scientific by 0.4% during the third quarter. Aviance Capital Partners LLC now owns 13,322 shares of the medical research company's stock valued at $8,240,000 after purchasing an additional 54 shares during the last quarter. 89.23% of the stock is owned by institutional investors and hedge funds.

Remove Ads

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 3,775 shares of the stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This represents a 25.87 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Stephen Williamson sold 9,825 shares of the company's stock in a transaction that occurred on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $5,753,421.75. Following the sale, the chief financial officer now directly owns 27,296 shares of the company's stock, valued at $15,984,264.64. The trade was a 26.47 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 23,900 shares of company stock worth $13,106,062. Insiders own 0.34% of the company's stock.

Thermo Fisher Scientific Stock Down 0.1 %

Shares of TMO traded down $0.60 during trading hours on Friday, reaching $518.04. The company's stock had a trading volume of 2,159,706 shares, compared to its average volume of 1,540,546. The firm has a market cap of $195.44 billion, a price-to-earnings ratio of 31.34, a P/E/G ratio of 2.99 and a beta of 0.79. Thermo Fisher Scientific Inc. has a 1-year low of $493.30 and a 1-year high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a 50 day moving average of $546.15 and a two-hundred day moving average of $555.91.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last released its quarterly earnings data on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be issued a $0.43 dividend. The ex-dividend date is Friday, March 14th. This represents a $1.72 dividend on an annualized basis and a yield of 0.33%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.39. Thermo Fisher Scientific's dividend payout ratio is currently 10.41%.

Wall Street Analyst Weigh In

Several analysts have weighed in on TMO shares. Morgan Stanley boosted their target price on shares of Thermo Fisher Scientific from $647.00 to $678.00 and gave the company an "overweight" rating in a research note on Friday, January 31st. Scotiabank boosted their price target on shares of Thermo Fisher Scientific from $605.00 to $650.00 and gave the company a "sector perform" rating in a report on Monday, February 3rd. Bank of America reduced their price target on shares of Thermo Fisher Scientific from $675.00 to $660.00 and set a "buy" rating for the company in a report on Friday, December 13th. UBS Group upped their price objective on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the stock a "buy" rating in a report on Friday, January 31st. Finally, Citigroup cut their price target on shares of Thermo Fisher Scientific from $650.00 to $570.00 and set a "neutral" rating for the company in a report on Tuesday, March 4th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has a consensus rating of "Moderate Buy" and a consensus target price of $653.23.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.